The trajectory of companies tied to Viagra's legacy presents a complex investment picture . While the initial surge generated substantial returns , generic competition have significantly eroded market share . Investing in connected pharmaceutical companies now requires a discerning assessment of patent rights , evolving healthcare shifts , and the